Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy

Pharmacogenomics

Volumn 7, Issue 3, 2006, Pages 281-297

  't Hoen, Peter A C ^a   van der Wees, Caroline G C ^a   Aartsma Rus, Annemieke ^a   Turk, Rolf ^a   Goyenvalle, Aurélie ^b   Danos, Olivier ^b   Garcia, Luis ^b   van Ommen, Gert Jan B ^a   den Dunnen, Johan T ^a   van Deutekom, Judith C T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GÉNÉTHON   (France)

Author keywords

Antisense ribonucleic acids; Duchenne muscular dystrophy; Dystrophin; Exon skipping; Mdx mouse; Microarray

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; FS 069; PARVOVIRUS VECTOR; POLYETHYLENEIMINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DNA MICROARRAY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; MOUSE; MYOFIBROSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; UNINDEXED SEQUENCE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; DRUG CARRIERS; EXONS; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

ADENO-ASSOCIATED VIRUS; ANIMALIA; PARVOVIRUS;

EID: 33646032109     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.3.281     Document Type: Article

References (36)

1. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G: Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet. 7, 1083-1090 (1998).
2. Takeshima Y, Nishio, H, Sakamoto H, Nakamura H, Matsuo M: Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in clystrophin Kobe. J. Clin. Invest. 95, 515-520 (1995).
3. van Deutekorn JC, Bremmer-Bout M, Janson AA et al.: Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 10, 1547-1554 (2001).
4. Aartsma-Rus A, Bremmer-Bout M, Janson AA et al.: Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12 (Suppl. 1), S71-S77 (2002).
5. Aartsma-Rus A, Janson AA, Kaman WE et al.: Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 12, 907-914 (2003).
6. Aartsma-Rus A, Janson AA, Kaman WE et al.: Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am. J. Hum. Genet. 74, 83-92 (2004).
7. Mann CJ, Honeyman K, Cheng AJ et al.: Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl Acad. Sci. USA 98, 42-47 (2001).
8. Lu QL, Mann CJ, Lou F et al.: Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nature Med. 9, 1009-1014 (2003).
9. Lu QL, Rabinowitz A, Chen YC et al: Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in bodywide skeletal muscles. Proc. Natl Acad. Sci. USA 102, 198-203 (2005).
10. Fletcher S, Honeyman K, Fall AM et al.: Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J. Gene Med. 8, 207-216 (2006).
11. Wells KE, Fletcher S, Mann CJ, Wilton SD, Wells DJ: Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle. FEBS Lett. 552, 145-149 (2003).
12. Takeshima Y, Yagi M, Wada H, Matsuo M: Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle. Brain Dev. 27, 488-493 (2005).
13. Goyenvalle A, Vulin A, Fougerousse F et al.: Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 1796-1799 (2004).
14. Wang L, Herzog RW: AAV-mediated gene transfer for treatment of hemophilia. Curr. Gene Ther. 5, 349-360 (2005).
15. Muntoni F, Bushby K, van Ommen G: 128th ENMC International Workshop on 'Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands. Neuromuscul. Discord. 15, 450-457 (2005).
16. Morris MJ, Tong WP, Cordon-Cardo C et al.: Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 8, 679-683 (2002).
17. Waters JS, Webb A, Cunningham D et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18, 1812-1823 (2000).
18. Chon H, Gaillard CA, van der Meijden BB et al.: Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension 43, 947-951 (2004).
19. Raju R, Dalakas MC: Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128, 1887-1896 (2005).
20. Turk R, Sterrenburg E, de Meijer EJ et al.: Muscle regeneration in dystrophin-deficient mdx mice studied by gene expression profiting. BMC Genomics 6, 98 (2005).
21. Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD: Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med 4, 644-654 (2002).
22. Bartoli M, Poupiot J, Goyenvalle A et al: Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies. Gene Ther. 13, 20-28 (2006).
23. Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ et al: Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oitgonucleotides. Mol. Ther. 10, 232-240 (2004).
24. 't Hoen PA, de Kort F, van Ommen GJ, den Dunnen JT. Fluorescent labeling of cRNA for microarray applications. Nucleic Acids Res. 31, e20 (2003).
25. Zhang B, Schmoyer D, Kirov S, Snoddy J: GOTree Machine (GOTM: a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics 5, l6 (2004).
26. Turk R, Sterrenburg E, van der Wees CG et al.: Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J. 20, 127-129 (2006).
27. Zanotti S, Negri T, Cappelletti C et al.: Decorin and biglycan expression is differentially altered in several muscular dystrophies. Brain 128, 2546-2555 (2005).
28. Wang M, Orsini C, Casanova D et al.: MUSEAP, a novel reporter gene for the study of long-term gene expression in immunocompetent mice. Gene 279,99-108 (2001).
29. Bakay M, Zhao P, Chen J, Hoffman EP: A web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscul. Disord. 12(Suppl. 1), S125-Sl4l (2002).
30. Haslett JN, Sanoudou D, Kho AT et al.: Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc. Natl Acad. Sci. USA 99, 15000-15005 (2002).
31. Porter JD, Khanna S, Kaminski HJ et al.: A chronic inflammatory response dominates the skeletal muscle molecular signature In dystrophin-deficient mdx mice. Hum. Mol. Genet. 11, 263-272 (2002).
32. Vaittinen S, Lukka R, Sahlgren C et al.: The expression of intermediate filament protein nestin as related to vimentin and desmin in regenerating skeletal muscle. J. Neuropathol. Exp. Neurol. 60, 588-597 (2001).
33. Vater R, Cullen MJ, Harris JB: The expression of vimentin in satellite cells of regenerating skeletal muscle in vivo. Histocbem. J. 26, 916-928 (1994).
34. Ezendam J, Staedtler F, Pennings J et al.: Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats. Environ. Health Perspect. 112, 782-791 (2004).
35. Kier LD, Neft R, Tang L et al.: Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutat. Res. 549, 101-113 (2004).
36. Waring JF, Gum R, Morfitt D et al.: Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor. Toxicology 181-182, 537-550 (2002).